https://www.biopharmawatch.com/news/MRNA/moderna-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-06T00:00:00.000Z Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026 https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-third-quarter-results-2026 BiopharmaWatch en 2026-10-28T00:00:00.000Z ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026 https://www.biopharmawatch.com/news/ASTH/alignment-health-plan-asth-partner-expand-access-care BiopharmaWatch en 2026-10-19T15:00:00.000Z Alignment Health Plan and Astrana Health Partner to Expand Access to Trusted Local Care for California Seniors https://www.biopharmawatch.com/news/SNY/sanofi-2026-ispe-facility-of-the-year-award BiopharmaWatch en 2026-10-19T14:03:00.000Z ISPE Names Sanofi S.A. the 2026 ISPE Facility of the Year Awards (FOYA) Overall Winner for its Modulus Project https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-renmark-roadshow-october-2026 BiopharmaWatch en 2026-10-19T13:54:27.000Z Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series https://www.biopharmawatch.com/news/BCDA/biocardia-fda-acceptance-helix-catheter BiopharmaWatch en 2026-10-19T13:15:00.000Z BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-kidney-week-2026-advancements BiopharmaWatch en 2026-10-19T13:00:00.000Z Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026 https://www.biopharmawatch.com/news/RXST/rxsight-appoints-eye-care-leaders-commercial-transformation BiopharmaWatch en 2026-10-19T13:00:00.000Z RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation https://www.biopharmawatch.com/news/XBIT/xbiotech-positive-phase-ii-results-taskin-trial BiopharmaWatch en 2026-10-19T13:00:00.000Z XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer https://www.biopharmawatch.com/news/DARE/dare-bioscience-hermedicine-educational-program BiopharmaWatch en 2026-10-19T12:56:00.000Z Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer https://www.biopharmawatch.com/news/ONMD/onemednet-signs-global-pharmaceutical-intelligence-partner BiopharmaWatch en 2026-10-19T12:45:00.000Z OneMedNet Signs Global Pharmaceutical Intelligence Provider as Channel Partner, Extending Reach in Pharma Market https://www.biopharmawatch.com/news/SPRC/scisparc-shifts-focus-agentic-ai-cybersecurity-finance BiopharmaWatch en 2026-10-19T12:35:00.000Z SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications https://www.biopharmawatch.com/news/FBLG/fibrobiologics-preclinical-data-fsdc-spheroids-nass-2026 BiopharmaWatch en 2026-10-19T12:30:00.000Z FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting https://www.biopharmawatch.com/news/DWTX/dogwood-secures-5-million-investment-ck-life-sciences BiopharmaWatch en 2026-10-19T12:30:00.000Z Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc. https://www.biopharmawatch.com/news/WVE/wave-life-sciences-virtual-research-day-november-2026 BiopharmaWatch en 2026-10-19T12:30:00.000Z Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026 https://www.biopharmawatch.com/news/INDV/indivior-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-19T12:30:00.000Z Indivior to Report Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SUPN/supernus-announces-q3-2026-results-conference-call BiopharmaWatch en 2026-10-19T12:30:00.000Z Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026 https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-ketamine-manufacturing-validation BiopharmaWatch en 2026-10-19T12:30:00.000Z NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine https://www.biopharmawatch.com/news/NRSN/neurosense-patent-application-traumatic-brain-injury BiopharmaWatch en 2026-10-19T12:25:00.000Z NeuroSense Files U.S. Patent Application for Traumatic Brain Injury https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-crohns-disease-data BiopharmaWatch en 2026-10-19T12:23:00.000Z Johnson & Johnson announces new TREMFYA® (guselkumab) data showing durable 3-year outcomes in moderate to severe Crohn’s disease and expanding evidence in perianal fistula https://www.biopharmawatch.com/news/ENLV/enlivex-cost-reduction-phase-2b-trial-allocetra-knee-oa BiopharmaWatch en 2026-10-19T12:17:00.000Z Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis https://www.biopharmawatch.com/news/RIGL/rigel-gavreto-data-esmo-congress-2026 BiopharmaWatch en 2026-10-19T12:05:00.000Z Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026 https://www.biopharmawatch.com/news/SER/enable-injections-approval-japan-circliq-injector BiopharmaWatch en 2026-10-19T12:04:00.000Z Enable Injections Announces Approval in Japan for CirCLIQ® Injector based on enFuse® On-Body Delivery System https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-phase-1a-ttx-mc138-esmo-2026 BiopharmaWatch en 2026-10-19T12:04:00.000Z TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026 https://www.biopharmawatch.com/news/AVBP/firmonertinib-egfr-pacc-mutant-nsclc-results BiopharmaWatch en 2026-10-19T12:01:00.000Z ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-crohns-disease-fistula-remission BiopharmaWatch en 2026-10-19T12:00:00.000Z Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula https://www.biopharmawatch.com/news/INVA/innoviva-specialty-therapeutics-idweek-2026 BiopharmaWatch en 2026-10-19T12:00:00.000Z Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026 https://www.biopharmawatch.com/news/ESTA/establishment-labs-q3-2026-financial-results-announcement BiopharmaWatch en 2026-10-19T12:00:00.000Z Establishment Labs® to Announce Third Quarter 2026 Financial Results on October 29 https://www.biopharmawatch.com/news/GILD/gilead-present-new-data-hiv-antiviral-idweek-2026 BiopharmaWatch en 2026-10-19T12:00:00.000Z Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026 https://www.biopharmawatch.com/news/SLN/merck-acquires-silence-therapeutics-sirna-asset BiopharmaWatch en 2026-10-19T12:00:00.000Z Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset https://www.biopharmawatch.com/news/SLN/silence-therapeutics-acquired-merck-kgaa BiopharmaWatch en 2026-10-19T12:00:00.000Z Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany https://www.biopharmawatch.com/news/RDHL/nci-grant-redhill-opaganib-car-t-cell-multiple-myeloma BiopharmaWatch en 2026-10-19T12:00:00.000Z $2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-cvr-trading-update BiopharmaWatch en 2026-10-19T12:00:00.000Z Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today https://www.biopharmawatch.com/news/IMMP/immutep-imp761-poster-acr-convergence-2026 BiopharmaWatch en 2026-10-19T12:00:00.000Z Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026 https://www.biopharmawatch.com/news/BIVI/biovie-bezisterim-long-covid-ana-2026 BiopharmaWatch en 2026-10-19T12:00:00.000Z BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting https://www.biopharmawatch.com/news/ALT/altimmune-pemvidutide-aasld-2026 BiopharmaWatch en 2026-10-19T12:00:00.000Z Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026 https://www.biopharmawatch.com/news/RMD/resmed-launch-airtouch-f40-cpap-mask-us BiopharmaWatch en 2026-10-19T12:00:00.000Z Resmed Launches AirTouch™ F40 Full Face Fabric CPAP Mask in the U.S. https://www.biopharmawatch.com/news/HYPD/hyperion-defi-third-quarter-earnings-call-november-2026 BiopharmaWatch en 2026-10-19T12:00:00.000Z Hyperion DeFi Schedules Third Quarter Earnings Call for Thursday, November 12 at 8:00 a.m. ET https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-enozertinib-esmo-congress-2026 BiopharmaWatch en 2026-10-19T12:00:00.000Z ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026 https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-cardiology-conferences BiopharmaWatch en 2026-10-19T12:00:00.000Z Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-q3-2026-financial-results-update BiopharmaWatch en 2026-10-19T12:00:00.000Z Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026 https://www.biopharmawatch.com/news/URGN/urogen-fda-acceptance-ugn-103-application BiopharmaWatch en 2026-10-19T12:00:00.000Z UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-esmo-congress-2026 BiopharmaWatch en 2026-10-19T12:00:00.000Z Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026 https://www.biopharmawatch.com/news/SGP/spyglass-pharma-positive-4-year-data-bim-iol-system BiopharmaWatch en 2026-10-19T12:00:00.000Z SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System https://www.biopharmawatch.com/news/BDMD/baird-medical-regulatory-milestones-vietnam-egypt BiopharmaWatch en 2026-10-19T12:00:00.000Z Baird Medical Announces Regulatory Milestones in Vietnam and Egypt, Expanding International Reach of Microwave Ablation Technology https://www.biopharmawatch.com/news/CLNN/clene-nda-submission-cnm-au8-als BiopharmaWatch en 2026-10-19T12:00:00.000Z Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS https://www.biopharmawatch.com/news/NYXH/nyxoah-q3-2026-results-revenue-guidance-adjustment BiopharmaWatch en 2026-10-19T12:00:00.000Z Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026 https://www.biopharmawatch.com/news/ARGX/argenx-phase-3-alkivia-results-acr-convergence-2026 BiopharmaWatch en 2026-10-19T12:00:00.000Z argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026 https://www.biopharmawatch.com/news/DMAC/diamedica-kol-webinar-update-fetal-growth-restriction BiopharmaWatch en 2026-10-19T12:00:00.000Z DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar https://www.biopharmawatch.com/news/DGX/current-screening-thresholds-miss-patients-primary-aldosterone BiopharmaWatch en 2026-10-19T11:57:00.000Z Current Screening Thresholds May Miss Half of Patients with Primary Aldosterone, a Leading Cause of Severe High Blood Pressure, Finds Study in Hypertension https://www.biopharmawatch.com/news/NVO/novo-nordisk-s-share-repurchase-programme-20261019 BiopharmaWatch en 2026-10-19T11:53:00.000Z Novo Nordisk A/S - share repurchase programme https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-atnm-400-eanm-2026 BiopharmaWatch en 2026-10-19T11:30:00.000Z Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026 https://www.biopharmawatch.com/news/FTH/faeth-present-preclinical-data-piktor-esmo-2026 BiopharmaWatch en 2026-10-19T11:30:00.000Z Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026 https://www.biopharmawatch.com/news/OGN/organon-third-quarter-2026-results-form-10-q BiopharmaWatch en 2026-10-19T11:30:00.000Z Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing https://www.biopharmawatch.com/news/BWAY/brainsway-collaboration-inland-psychiatry BiopharmaWatch en 2026-10-19T11:30:00.000Z BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group https://www.biopharmawatch.com/news/GLAS/glass-house-brands-q3-2026-results-resignation BiopharmaWatch en 2026-10-19T11:30:00.000Z Glass House Brands Reports Preliminary Unaudited Third Quarter Financial Results and Resignation of John Nichols Jr. from Board of Directors https://www.biopharmawatch.com/news/CYTK/cytokinetics-health-canada-approval-myorzo BiopharmaWatch en 2026-10-19T11:30:00.000Z Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy https://www.biopharmawatch.com/news/BIIB/biogen-present-new-data-nephrology-portfolio-asn-kidney-week BiopharmaWatch en 2026-10-19T11:30:00.000Z Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week https://www.biopharmawatch.com/news/CRMD/cormedix-fda-acceptance-rezzayo-prophylaxis-fungal-diseases BiopharmaWatch en 2026-10-19T11:30:00.000Z Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases https://www.biopharmawatch.com/news/EYPT/eyepoint-announces-strategic-prioritization BiopharmaWatch en 2026-10-19T11:15:00.000Z EyePoint Announces Strategic Prioritization https://www.biopharmawatch.com/news/XNCR/xencor-webcast-phase-1-xmab819-results BiopharmaWatch en 2026-10-19T11:01:00.000Z Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma https://www.biopharmawatch.com/news/AZN/astrazeneca-esmo-2026-pivotal-phase-iii-trials BiopharmaWatch en 2026-10-19T11:00:00.000Z AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib https://www.biopharmawatch.com/news/MANE/veradermics-vdphl01-phase-3-hair-loss-trial BiopharmaWatch en 2026-10-19T11:00:00.000Z Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-phase-ii-study-ivonescimab-ccrcc BiopharmaWatch en 2026-10-19T11:00:00.000Z Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma https://www.biopharmawatch.com/news/UTHR/united-therapeutics-fda-clearance-summit-trial BiopharmaWatch en 2026-10-19T11:00:00.000Z United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD https://www.biopharmawatch.com/news/CGEM/zipalertinib-nsclc-egfr-cns-metastases BiopharmaWatch en 2026-10-19T11:00:00.000Z Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases https://www.biopharmawatch.com/news/INSM/insmed-launches-brinsupr-tablets-japan BiopharmaWatch en 2026-10-19T11:00:00.000Z Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan https://www.biopharmawatch.com/news/IOVA/iovance-til-cell-therapy-esmo-congress-2026 BiopharmaWatch en 2026-10-19T11:00:00.000Z Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026 https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-tonmya-presentation-iasp-2026 BiopharmaWatch en 2026-10-19T11:00:00.000Z Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain https://www.biopharmawatch.com/news/ATYR/atyr-pharma-research-collaboration-montefiore-einstein BiopharmaWatch en 2026-10-19T11:00:00.000Z aTyr Pharma Announces Research Collaboration with Montefiore Einstein https://www.biopharmawatch.com/news/PBLS/parabilis-medicines-esmo-congress-2026-zolucatetide BiopharmaWatch en 2026-10-19T11:00:00.000Z Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026 https://www.biopharmawatch.com/news/KMDA/kamada-participation-stifel-jefferies-conferences-november-2026 BiopharmaWatch en 2026-10-19T11:00:00.000Z Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026 https://www.biopharmawatch.com/news/IRON/disc-medicine-apollo-trial-results-bitopertin-epp BiopharmaWatch en 2026-10-19T11:00:00.000Z Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP) https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-educational-event-pkp2-acm BiopharmaWatch en 2026-10-19T11:00:00.000Z Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-fda-grant-mt-601-pancreatic-cancer BiopharmaWatch en 2026-10-19T11:00:00.000Z Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer https://www.biopharmawatch.com/news/EYPT/eyepoint-lucia-phase-3-results-duravyu-wet-amd BiopharmaWatch en 2026-10-19T11:00:00.000Z EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD https://www.biopharmawatch.com/news/HLN/haleon-health-house-interactive-wellness-popup-toronto BiopharmaWatch en 2026-10-19T11:00:00.000Z Haleon Launches ‘Haleon Health House,’ a One-Day Interactive Wellness Pop-Up in Toronto https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-esmo-2026-cancer-modalities BiopharmaWatch en 2026-10-19T10:59:00.000Z Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026 https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-launch-duloxetine-capsules BiopharmaWatch en 2026-10-19T10:55:00.000Z ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules https://www.biopharmawatch.com/news/BNTX/biontech-esmo-2026-oncology-pipeline-progress BiopharmaWatch en 2026-10-19T10:45:00.000Z BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026 https://www.biopharmawatch.com/news/CAI/caris-life-sciences-launches-ai-cancer-detection-commercial BiopharmaWatch en 2026-10-19T10:30:00.000Z Caris Life Sciences Launches New National Commercial Featuring Jordan Spieth Highlighting the Power of Artificial Intelligence in Early Stage Cancer Detection https://www.biopharmawatch.com/news/IMUX/immunic-appoints-jaa-roberson-chief-people-officer BiopharmaWatch en 2026-10-19T10:30:00.000Z Immunic Appoints Jaa Roberson as Chief People Officer https://www.biopharmawatch.com/news/SNY/sanofi-insulin-manufacturing-facility-germany BiopharmaWatch en 2026-10-19T10:30:00.000Z Press Release: Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany https://www.biopharmawatch.com/news/ONC/beone-medicines-esmo-2026-solid-tumor-franchise BiopharmaWatch en 2026-10-19T10:00:00.000Z BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026 https://www.biopharmawatch.com/news/IDYA/darovasertib-potential-foundational-therapy-uveal-melanoma BiopharmaWatch en 2026-10-19T10:00:00.000Z IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma https://www.biopharmawatch.com/news/ZYME/zymeworks-appoints-suzanne-monahan-svp-commercial BiopharmaWatch en 2026-10-19T10:00:00.000Z Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma https://www.biopharmawatch.com/news/BDSX/biodesix-digital-diagnostics-lung-pipeline BiopharmaWatch en 2026-10-19T10:00:00.000Z Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers https://www.biopharmawatch.com/news/BLTE/belite-bio-uplisting-nasdaq-global-select-market BiopharmaWatch en 2026-10-19T10:00:00.000Z Belite Bio Announces Uplisting to the Nasdaq Global Select Market https://www.biopharmawatch.com/news/TAK/entivyo-ulcerative-colitis-trial-results BiopharmaWatch en 2026-10-19T09:30:00.000Z First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication https://www.biopharmawatch.com/news/NUTX/nutex-health-2026-q3-financial-results-call BiopharmaWatch en 2026-10-19T09:30:00.000Z Nutex Health Schedules 2026 Third Quarter Financial Results Release and Conference Call https://www.biopharmawatch.com/news/LLY/lilly-omvoh-phase-3-results-pediatric-ulcerative-colitis BiopharmaWatch en 2026-10-19T08:40:00.000Z Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis https://www.biopharmawatch.com/news/ABBV/abbvie-abbv-466-crohns-disease-results BiopharmaWatch en 2026-10-19T08:00:00.000Z AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-10-19 BiopharmaWatch en 2026-10-19T07:15:25.407Z BIOA APJ program: Biotech Catalysts Oct 19, 2026 https://www.biopharmawatch.com/news/WAT/ultima-genomics-immune-profiling-study-uk-biobank BiopharmaWatch en 2026-10-19T07:05:00.000Z Ultima Genomics Selected for Landmark Large-Scale Immune Profiling Study with IMU Biosciences, UK Biobank and Waters Corporation https://www.biopharmawatch.com/news/EVAX/evaxion-three-year-follow-up-phase-2-trial-evx-01 BiopharmaWatch en 2026-10-19T07:00:00.000Z Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 https://www.biopharmawatch.com/news/OCS/oculis-predict-1-trial-licaminlimab-dry-eye BiopharmaWatch en 2026-10-19T06:00:00.000Z Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease https://www.biopharmawatch.com/news/TLX/telix-ekalia-collaborate-astatine-211-production-us BiopharmaWatch en 2026-10-19T05:30:00.000Z Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S. https://www.biopharmawatch.com/news/NTRA/natera-esmo-2026-abstracts-ultrasensitive-mrd-technology BiopharmaWatch en 2026-10-18T22:10:00.000Z ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology https://www.biopharmawatch.com/news/ABBV/abbvie-esmo-2026-oncology-data-presentation BiopharmaWatch en 2026-10-18T22:10:00.000Z AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio https://www.biopharmawatch.com/news/LLY/lilly-showcase-oncology-pipeline-esmo-2026 BiopharmaWatch en 2026-10-18T22:05:00.000Z Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress https://www.biopharmawatch.com/news/INCY/incyte-oncology-data-esmo-congress-2026 BiopharmaWatch en 2026-10-18T22:05:00.000Z Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 https://www.biopharmawatch.com/news/ZNTL/zentalis-azenosertib-overall-survival-data-esmo-2026 BiopharmaWatch en 2026-10-18T22:05:00.000Z Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-abstracts-esmo-congress-2026 BiopharmaWatch en 2026-10-18T22:05:00.000Z Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress https://www.biopharmawatch.com/news/MANE/veradermics-conference-call-phase-3-results-hair-loss BiopharmaWatch en 2026-10-18T22:00:00.000Z Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss https://www.biopharmawatch.com/news/IRON/disc-medicine-webcast-apollo-phase-3-results BiopharmaWatch en 2026-10-18T21:00:00.000Z Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP) https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-uegw-2026-presentations BiopharmaWatch en 2026-10-18T13:30:00.000Z Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026